当前位置: X-MOL 学术J. Biopharm. Stat. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A Bayesian approach to benefit-risk assessment in clinical studies with longitudinal data.
Journal of Biopharmaceutical Statistics ( IF 1.1 ) Pub Date : 2020-02-25 , DOI: 10.1080/10543406.2020.1726370
Dongyan Yan 1 , Chul Ahn 2 , Shabnam Azadeh 2 , Mourad Atlas 2 , Ram Tiwari 2
Affiliation  

Chuang-Stein et al. proposed a method for benefit-risk assessment by formulating a five-category multinomial random variable with the first four categories as a combination of benefit and risk, and the fifth category to include subjects who withdraw from study. In this article, we subdivide the single withdrawal category into four sub-categories to consider withdrawal for different reasons. To analyze eight-category data, we propose a two-level multivariate-Dirichlet Model to identify benefit-risk measures at the population level. For individual benefit-risk, we use a log-odds ratio model with Dirichlet process prior. Two methods are applied to a hypothetical clinical trial data for illustration.

中文翻译:

使用纵向数据在临床研究中进行收益风险评估的贝叶斯方法。

Chuang-Stein等。提出了一种利益风险评估方法,该方法通过制定一个五类多项式随机变量,其中前四类为利益和风险的组合,第五类包括退出研究的对象。在本文中,我们将单个提款类别细分为四个子类别,以出于不同原因考虑提款。为了分析八类数据,我们提出了一个两级多元Dirichlet模型来识别人口水平上的利益风险度量。对于个人利益风险,我们先使用Dirichlet过程的对数比模型。将两种方法应用于假设的临床试验数据以进行说明。
更新日期:2020-02-25
down
wechat
bug